SS-31 (Elamipretide)
Cationic aromatic peptide that penetrates the mitochondria and stabilises Cardiolipin (inner membrane phospholipid). Restores the electron transport chain and reduces ROS.
- Restoration of mitochondrial function (ATP)
- Cardiac and renal rejuvenation
- Reduction of chronic fatigue
- Protection against ischaemiaRestoration of mitochondrial function (ATP)
- Protection against ischaemia
- Irritation at the injection site (common).
SS-31, also known as Elamipretide, is a small peptide that easily crosses cell membranes and binds specifically to cardiolipin in the inner mitochondrial membrane, stabilising energy production.
READ MORE
What it is (in plain language)
- It's a 'mechanic' for your cellular batteries (mitochondria). When mitochondria are damaged by ageing or disease, they produce 'rubbish' (free radicals) and little energy. SS-31 repairs the internal structure of these batteries, allowing them to produce clean, efficient energy again.
Why do you appear online so much
- It is the emerging star of mitochondrial medicine. It is rumoured to treat rare diseases, kidney problems, heart failure and even visual decline, as it acts at the energetic root of cell survival.
How it is framed today (pragmatic view)
- 1) Evidence: Advanced clinical trials for various degenerative diseases. 2) Objective: Mitochondrial rehabilitation and reduction of profound oxidative stress. 3) Risk: Generally well tolerated; the focus is on clinical application for chronic conditions.
How to use this form
- Check out the mitochondrial function diagrams in our knowledge base.
- Quick profile (curated by Subject 157)
- Class: Repair
- Status: Verified
- Use case: Repair
- Route: Injectable
- Tags: Injectable|Mitochondria|Longevity
- Half-life: ~2-3 Hours
- Start: Fast
- Duration: Variable
- Mechanism (high level)
Cationic aromatic peptide that penetrates the mitochondria and stabilises Cardiolipin (inner membrane phospholipid). Restores the electron transport chain and reduces ROS.
- Evidence (what the literature covers)
RESEARCH RANGE (Clinical, Non-prescriptive):
Studied in heart failure and myopathies. Doses of 40mg SC daily.
Level of Evidence: A (Active Clinical Trials).
- Safety and harm-reduction (non-prescriptive)
Risks: Irritation at the injection site (common).
Interactions: Unknown.
- References (anchors)
- Szeto, H. H. (2013) - SS-31 and mitochondrial energetics - https://doi.org/10.1681/ASN.2012121216 | PubMed:23348123
- Zhang, H. (2018) - SS-31 reduces neuroinflammation - https://doi.org/10.1212/WNL.0000000000005255 | PubMed:29540582
Note: Educational/research content. Does not constitute medical advice, diagnosis or prescription.
EN 
PT 
FR 
ES 
DE 
IT 
PL